Menu

First Dengue Vax Approved

Mexico’s health ministry has OKed the vaccine for people between nine and 45 years old.

Dec 11, 2015
Kerry Grens

FREE STOCK PHOTOS, CDC/PROF FRANK HADLEY COLLINSMexico has approved the world’s first dengue virus vaccine. Sanofi’s Dengvaxia will be available to children over nine and adults 45 and under.

“We are making dengue a preventable disease, which makes us incredibly proud,” Olivier Charmeil, the head of vaccines at Sanofi, told Bloomberg Business.

According to the World Health Organization, 2.35 million people in the Americas contracted the mosquito-borne illness in 2013. Dengue can cause high fever, muscle pains, vomiting, and, in some cases, death.

Sanofi spent two decades and $1.6 billion on the development of Dengvaxia. According to BBC News, about 40,000 people in Mexico will initially receive the shot. “With this decision, Mexico moves ahead of all other countries, including France, to tackle the spread of this virus,” the country’s health ministry in a statement.

Results of a clinical trial among children found the vaccine is about 60 percent effective at warding off dengue virus.

The price of the immunization has not been disclosed. More than a dozen other countries are considering approval, according to Bloomberg News.

Update (December 29): Health officials in Brazil and the Philippines have also approved the use of Dengvaxia, Sanofi Pasteur announced over the past week.

“Approval of the first dengue vaccine is an important public health breakthrough with critical importance to our country, which bears the greatest dengue burden in Latin America,” Joao Bosco Siqueira Junior of the Federal University of Goias, Brazil, said in the press release.

Dengue cases in Brazil erupted in 2015, topping 1.5 million, compared to roughly 500,000 in 2014, The Wall Street Journal reported. Asia, however, bears the brunt of dengue fever, with 70 percent of infections occurring there.

It’s not clear when the vaccine will become available in the countries that have authorized its distribution.

September 2018

The Muscle Issue

The dynamic tissue reveals its secrets

Marketplace

Sponsored Product Updates

StemExpress LeukopakâNow Available in Frozen Format

StemExpress LeukopakâNow Available in Frozen Format

StemExpress, a Folsom, California based leading supplier of human biospecimens, announces the release of frozen Peripheral Blood Leukopaks. Leukopaks provide an enriched source of peripheral blood mononuclear cells (PBMCs) with low granulocyte and red blood cells that can be used in a variety of downstream cell-based applications.

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

Vector Laboratories, a leader in the development and manufacture of labeling and detection reagents for biomedical research, introduces VECTASHIELD® Vibrance™ – antifade mounting media that delivers significant improvements to the immunofluorescence workflow.

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Download this white paper from Bertin Technologies to learn how to extract and analyze lipid samples from various models!

Bio-Rad Launches CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin for Process Protein Purification

Bio-Rad Launches CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin for Process Protein Purification

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the launch of two new chromatography media for process protein purification: CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin.